Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NextCureFRA:2US0 27 Pretax Margin % is % as of Mar. 2026. GuruFocus rates FRA:2US0 with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 942 Biotechnology companies, NextCure ranks worse than 106157.01% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. NextCure's Pre-Tax Income for the
three
months ended in Mar. 2026 was €-8.47 Mil. NextCure's Revenue for the
three
months ended in Mar. 2026 was €0.00 Mil. Therefore, NextCure's pretax margin for the quarter that ended in Mar. 2026 was %.
The historical rank and industry rank for NextCure's Pretax Margin % or its related term are showing as below:
FRA:2US0's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -90.5 * Ranked among companies with meaningful Pretax Margin % only.
NextCure (FRA:2US0) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
NextCure Pretax Margin % Related Terms
NextCure Pretax Margin % Historical Data
* Premium members only.
The historical data trend for NextCure's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2US0 vs LPCN, VYNE, QNCX: Pretax Margin % Comparison
For the Biotechnology subindustry, NextCure's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NextCure Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NextCure's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where NextCure's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NextCure (FRA:2US0) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on NextCure and its competitors. According to the industry distribution chart, NextCure ranks #999999 out of 942 companies in the Biotechnology industry.
Is NextCure's Pretax Margin % too high?
NextCure's current Pretax Margin % is %. Based on the distribution chart, NextCure ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NextCure has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does NextCure's Pretax Margin % compare to LPCN and VYNE?
According to the Biotechnology industry distribution chart, NextCure ranks #999999 out of 942 companies for Pretax Margin %. This places NextCure in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on NextCure and its competitors. NextCure's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCure stock overvalued right now?
NextCure (FRA:2US0) has a current Pretax Margin % of %. The current Pretax Margin % is %. NextCure's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For NextCure (FRA:2US0), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
27GF Score
Get the complete analysis for FRA:2US0
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2US0 has been successfully added to your 
